Harper Sean E 4
Accession 0001104659-24-024091
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 5:35 PM ET
Size
23.9 KB
Accession
0001104659-24-024091
Insider Transaction Report
- Conversion
Common Stock
2024-02-12+3,787,940→ 3,787,940 total(indirect: See Footnote) - Conversion
Common Stock
2024-02-12+735,984→ 735,984 total(indirect: See Footnote) - Conversion
Series A-1 Redeemable Convertible Preferred Stock
2024-02-12−4,401,771→ 0 total(indirect: See Footnote)→ Common Stock (967,188 underlying) - Conversion
Series A-2 Redeemable Convertible Preferred Stock
2024-02-12−8,830,901→ 0 total(indirect: See Footnote)→ Common Stock (1,940,388 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−4,006,624→ 0 total(indirect: See Footnote)→ Common Stock (880,364 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−3,349,538→ 0 total(indirect: See Footnote)→ Common Stock (735,984 underlying)
- Conversion
Common Stock
2024-02-12+3,787,940→ 3,787,940 total(indirect: See Footnote) - Conversion
Common Stock
2024-02-12+735,984→ 735,984 total(indirect: See Footnote) - Conversion
Series A-1 Redeemable Convertible Preferred Stock
2024-02-12−4,401,771→ 0 total(indirect: See Footnote)→ Common Stock (967,188 underlying) - Conversion
Series A-2 Redeemable Convertible Preferred Stock
2024-02-12−8,830,901→ 0 total(indirect: See Footnote)→ Common Stock (1,940,388 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−4,006,624→ 0 total(indirect: See Footnote)→ Common Stock (880,364 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−3,349,538→ 0 total(indirect: See Footnote)→ Common Stock (735,984 underlying)
- Conversion
Common Stock
2024-02-12+3,787,940→ 3,787,940 total(indirect: See Footnote) - Conversion
Common Stock
2024-02-12+735,984→ 735,984 total(indirect: See Footnote) - Conversion
Series A-1 Redeemable Convertible Preferred Stock
2024-02-12−4,401,771→ 0 total(indirect: See Footnote)→ Common Stock (967,188 underlying) - Conversion
Series A-2 Redeemable Convertible Preferred Stock
2024-02-12−8,830,901→ 0 total(indirect: See Footnote)→ Common Stock (1,940,388 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−4,006,624→ 0 total(indirect: See Footnote)→ Common Stock (880,364 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−3,349,538→ 0 total(indirect: See Footnote)→ Common Stock (735,984 underlying)
- Conversion
Common Stock
2024-02-12+3,787,940→ 3,787,940 total(indirect: See Footnote) - Conversion
Common Stock
2024-02-12+735,984→ 735,984 total(indirect: See Footnote) - Conversion
Series A-1 Redeemable Convertible Preferred Stock
2024-02-12−4,401,771→ 0 total(indirect: See Footnote)→ Common Stock (967,188 underlying) - Conversion
Series A-2 Redeemable Convertible Preferred Stock
2024-02-12−8,830,901→ 0 total(indirect: See Footnote)→ Common Stock (1,940,388 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−4,006,624→ 0 total(indirect: See Footnote)→ Common Stock (880,364 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−3,349,538→ 0 total(indirect: See Footnote)→ Common Stock (735,984 underlying)
- Conversion
Common Stock
2024-02-12+3,787,940→ 3,787,940 total(indirect: See Footnote) - Conversion
Common Stock
2024-02-12+735,984→ 735,984 total(indirect: See Footnote) - Conversion
Series A-1 Redeemable Convertible Preferred Stock
2024-02-12−4,401,771→ 0 total(indirect: See Footnote)→ Common Stock (967,188 underlying) - Conversion
Series A-2 Redeemable Convertible Preferred Stock
2024-02-12−8,830,901→ 0 total(indirect: See Footnote)→ Common Stock (1,940,388 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−4,006,624→ 0 total(indirect: See Footnote)→ Common Stock (880,364 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2024-02-12−3,349,538→ 0 total(indirect: See Footnote)→ Common Stock (735,984 underlying)
Footnotes (4)
- [F1]Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
- [F2]Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any.
- [F3]Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any.
- [F4]The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.
Documents
Issuer
Kyverna Therapeutics, Inc.
CIK 0001994702
Related Parties
1- filerCIK 0001541946
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 5:35 PM ET
- Size
- 23.9 KB